Israel’s Amenity Analytics gets US buyer; Nectin extends Series A

 Israel’s Amenity Analytics gets US buyer; Nectin extends Series A

Israeli startup Amenity Analytics, which develops natural language processing data, has been acquired by US-based fintech firm Symphony for an undisclosed amount.

All the 50 Amenity employees will join Symphony as part of the deal.

Amenity has raised $40 million over the last seven years that it has been in existence and has offices in the US and Israel. It is backed by the likes of American insurer Starr International Company, Allstate, Intel Capital, and State of Mind Ventures.

Amenity was founded in 2015 by chief executive officer Nathaniel Storch and Ronen and Hedva Feldman, who are no longer active in the company.

Symphony develops a markets’ infrastructure and technology platform, where solutions are built or integrated to standardize, automate and innovate financial services workflows.

Nectin Therapeutics

Israeli biotech company Nectin Therapeutics has extended its Series A funding round to more than $25 million.

Nectin, which develops novel targeted immunotherapies to address resistance to approved immuno-oncology treatments, was backed in the round by IBF and Peregrine Ventures, which led the funding round.

The two lead investors were joined in the round by aMoon Fund and other existing investors.

Nectin said it will use the new money to support the ongoing clinical evaluation of NTX1088, and to further advance the company’s pipeline of targeted immunotherapies and Antibody Drug Conjugates (ADCs).

The funding also comes even as the company has begun closing of the first patient in its Phase 1 clinical trial of NTX1088, its first-in-class PVR (CD155) blocker, in cancer patients with locally advanced and metastatic solid tumors.

“Nectin has developed a highly innovative pipeline that has the potential to fundamentally overcome the limitations of existing IO therapies, delivering new treatment options for patients suffering from difficult-to-treat cancers, and we look forward to the results of the Phase 1 clinical trial of NTX1088,” said Fabian Tenenbaum, CEO at Nectin.

Aman Malik

error: Content is protected !!
The Capital Quest